Voriconazole topical cream formulation: evidence for stability and antifungal activity - Université Paris Cité
Article Dans Une Revue International Journal of Antimicrobial Agents Année : 2020

Voriconazole topical cream formulation: evidence for stability and antifungal activity

Joël Schlatter

Résumé

Systemic use of voriconazole (VCZ) might be restricted by adverse events, such as hepatotoxicity and neurotoxicity, or drug-drug interactions. Topical VCZ application to skin may help to treat local infection more effectively and limit unwanted whole-body exposure. Topical VCZ cream was stable for 90 days when refrigerated. A patient with cutaneous Fusarium solani infection on his right forearm was successfully treated with topical 1% VCZ cream after failure of oral VCZ treatment.
Fichier principal
Vignette du fichier
S0924857920302533.pdf (419.75 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03492491 , version 1 (30-08-2022)

Licence

Identifiants

Citer

Camille Bouchand, David Nguyen, Philippe-Henri Secretan, Fabrice Vidal, Romain Guery, et al.. Voriconazole topical cream formulation: evidence for stability and antifungal activity. International Journal of Antimicrobial Agents, 2020, 56 (3), pp.106083. ⟨10.1016/j.ijantimicag.2020.106083⟩. ⟨hal-03492491⟩
73 Consultations
164 Téléchargements

Altmetric

Partager

More